Safety, Pharmacokinetics and Potential Activity of HE3286 in Obese Adult Subjects
Completed · Phase 1 · Has a placebo group
Conditions studied: Insulin Resistance
In brief
The objectives of this study are to evaluate the safety, tolerance and pharmacokinetics of HE3286 when administered daily for 28 days to obese adult subjects and to assess potential activity of HE3286 to decrease insulin resistance. An open-label cohort of 6 patients with type II diabetes mellitus will be treated at 10 mg (5 mg BID).
Key facts
- Study ID
- NCT00555451
- Run by
- Harbor Therapeutics
- People needed
- 66
- Starts
- 2007-10-01
- Expected to finish
- 2009-09-01
- Last updated by the study team
- 2010-05-13
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.
Where it is running
- Study site — Baton Rouge, Louisiana, United States
- dgd Research, Inc. — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.